Cristina Ghenoiu is a partner in Mubadala Capital’s venture business, focusing on biotech investments. She came to Mubadala from RA Capital, where she was a principal on the venture team. Prior to that, while a vice president on the biotech team at Longitude Capital, she helped spin out, amongst others, Rivus (scientific co-founder), 89bio (ETNB), and Epirium Bio, which she joined and served as senior vice president, R&D operations & new product planning. Before Longitude Capital, Cristina was an associate analyst in Biotechnology Equity Research at TD Cowen covering publicly traded large and smid cap biotech stocks. Cristina trained as a postdoc at The Rockefeller University, published first author papers in Science, Molecular Cell and JCB; holds a PhD in Chromosome and Cell Biology from Cornell University and a Bachelor of Arts in Biochemistry from Mount Holyoke College, Magna cum laude and High Honors for Computational Quantum Chemistry Thesis.